Johnson & Johnson (JNJ) Shares Sold by Cynosure Advisors LLC

Cynosure Advisors LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 8,743 shares of the company’s stock after selling 2,034 shares during the period. Cynosure Advisors LLC’s holdings in Johnson & Johnson were worth $1,120,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. TT International boosted its position in Johnson & Johnson by 254.1% in the 1st quarter. TT International now owns 136,518 shares of the company’s stock valued at $15,930,000 after buying an additional 97,969 shares during the period. Eagle Global Advisors LLC boosted its position in Johnson & Johnson by 1.6% in the 1st quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock valued at $9,927,000 after buying an additional 1,221 shares during the period. Great West Life Assurance Co. Can boosted its position in Johnson & Johnson by 1.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,784,116 shares of the company’s stock valued at $485,495,000 after buying an additional 72,159 shares during the period. Trexquant Investment LP boosted its position in Johnson & Johnson by 28.2% in the 1st quarter. Trexquant Investment LP now owns 22,542 shares of the company’s stock valued at $2,889,000 after buying an additional 4,959 shares during the period. Finally, NuWave Investment Management LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $680,000. 66.80% of the stock is owned by hedge funds and other institutional investors.

In related news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by company insiders.

Shares of JNJ opened at $139.49 on Friday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The firm has a market capitalization of $373.89 billion, a PE ratio of 19.11, a PEG ratio of 2.13 and a beta of 0.69. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the business earned $1.83 EPS. The company’s revenue was up 10.6% on a year-over-year basis. equities analysts expect that Johnson & Johnson will post 8.14 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th were issued a $0.90 dividend. The ex-dividend date was Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.58%. Johnson & Johnson’s payout ratio is 49.32%.

Several equities analysts have commented on the stock. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price target on shares of Johnson & Johnson in a research report on Friday. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Sanford C. Bernstein assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target for the company. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $142.87.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply